Question 1

What is the dosing protocol for thymosin alpha-1?

Accepted Answer

There is no dosing protocol for a person to follow among the research behind this page. There is one figure that trial teams used again and again. A 2001 review, written while it was still in late-stage trials, states that for hepatitis B and C, TA1 1.6 mg (900 micrograms/m2) should be administered subcutaneously twice a week. The second number in that line matters. It writes the same amount as a rate per square metre of body surface, a size measure doctors use for some medicines, and that tells you the figure was built for an adult patient of average build. It is also a sentence about two named liver infections. It was written for doctors treating hepatitis, in the language of a hospital formulary, and it does not describe a schedule for anybody without hepatitis. What follows on this page is what the studies gave, to whom, how often and for how long.

Question 2

What amounts did the published studies use?

Accepted Answer

The answer is almost the same figure every time, which is unusual and worth noticing. Across hepatitis B, seven randomized controlled studies on Talpha1 monotherapy gave 6 months treatment with Talpha1 (1.6 mg twice-weekly). In hepatitis C, 40 subjects received thymalfasin (1.6 mg twice a week), PEG-IFN alpha-2a (180 microg once a week), and ribavirin (800-1,000 mg/day) for 48 weeks. After bowel cancer surgery, one arm took 1.6 mg of thymalfasin for injection, twice a week, and the other took 1.6 mg of thymalfasin for injection, thrice a week. A 2026 trial in bowel cancer patients after chemotherapy used thymalfasin (1.6 mg subcutaneously twice weekly) for 8 weeks. Four settings, four sets of patients, and one figure per injection. Only the spacing and the length of the course move.

Question 3

Is there a thymosin alpha-1 dosage per day?

Accepted Answer

Only in one trial, and it was a hospital trial in people who were critically ill. Patients with severe pancreatitis were assigned to receive a subcutaneous injection of Tα1 1.6 mg every 12 h for the first 7 days and 1.6 mg once a day for the subsequent 7 days. So for one week those patients had two injections a day, and for the next week one. Every other study behind this page spaced the injections days apart. That trial's main question was the development of IPN during the index admission, and its conclusion was that Ta1 given this way did not reduce the incidence of IPN during the index admission. IPN is infection of dead pancreas tissue, and the index admission is the hospital stay in which the patient was enrolled. A daily schedule built for intensive care, which then missed its own main goal, is a weak place to borrow a daily figure from.

Question 4

Who received those amounts?

Accepted Answer

People who were already ill, every time, and in most studies seriously so. The hepatitis C cohort were Hispanic patients with chronic viral hepatitis C who were nonresponders to prior treatment with interferon alfa (IFN-alpha)/ribavirin. Nonresponders are people whose infection survived an earlier course of standard medicine. The bowel cancer trial took 400 patients who underwent radical resection of CRC, meaning surgery to remove the cancer, and gave them chemotherapy as well. The 2026 trial enrolled patients with CRC who completed chemotherapy, randomised so that 33 of them received thymalfasin. None of these people were healthy volunteers, and the amounts were chosen for them. That is the whole reason the figures cannot be carried across to a person in good health.

Question 5

Why twice a week if it clears from the blood within a day?

Accepted Answer

This is the puzzle in the schedule, and the published numbers make it plain. An early review reports that TA1 is rapidly absorbed, achieving peak serum concentrations within two hours. The same review adds that blood levels return to baseline within 24 hours, and the serum half-life is approximately 2 hours. So the peptide is gone from the blood long before the next injection, two or three days later. That makes sense only if the target is the immune response rather than the blood level, and a 2004 review notes that the benefits of Talpha1 therapy is usually not immediately apparent during therapy. The schedule assumes an effect that outlasts the molecule. That is a reasonable reading of the hepatitis work, and it is still an assumption about spacing rather than a tested result, because the one trial that varied the spacing, covered below, does not report its two arms against each other.

Question 6

How long did the courses run?

Accepted Answer

From two weeks to a year, and longer was not better in the one trial that checked. A randomized, controlled trial in hepatitis B found HBV DNA clearance in 40.6% and 25.6% of patients treated with TA1 for 6 and 12 months, against 9.4% of untreated controls. HBV DNA is the genetic material of the hepatitis B virus in the blood, so clearance means the test could no longer find the virus. Read that carefully. The year-long course cleared the virus in fewer patients than the six-month course, and both beat no treatment. One trial is not proof that longer courses do worse, but it is the opposite of more being better. The other lengths on record are 48 weeks in hepatitis C, 8 weeks after chemotherapy, and two weeks in pancreatitis, where it was given at 1.6 mg every 12 h for the first 7 days.

Question 7

Did giving it more often change anything?

Accepted Answer

One trial tested frequency, and its abstract does not separate the two arms. The bowel cancer study split its thymalfasin patients into a conventional-dose group and a high-dose group, the only difference being twice against three times a week. Compared with control group, the conventional-dose group and high-dose group had notably lower incidences of perioperative infection. Perioperative means around the time of the operation. Both arms beat chemotherapy alone on infection. What a reader wants from that design is the comparison between the arms, and the summary does not give one. The trial measured both against a control group rather than against each other in its reported results, so it does not tell you whether a third weekly injection added anything.

Question 8

Was there a starting amount, or a build-up?

Accepted Answer

No. Every study began at the full figure from the first injection. That is different from many injected medicines, where a small first amount is raised over weeks. The thymosin alpha-1 trials did the opposite where they changed anything at all. The pancreatitis schedule front-loaded the course, with Tα1 1.6 mg every 12 h for the first 7 days and 1.6 mg once a day for the subsequent 7 days. In the hepatitis C combination, the study reports that a reduction of the dose of PEG IFN alpha-2a and ribavirin was required, while the thymalfasin amount stayed where it started. So nothing in the published record lowers or raises the Ta1 amount in response to how a patient is doing. The partner medicines were adjusted; this one was not. Whether that reflects a lack of need or a lack of testing, the studies do not say.

Question 9

Is there a cycle, or a break, in the published work?

Accepted Answer

Each trial gave one course and then stopped. None of the studies covered here repeated a course after a break, so there is no cycle on record to report. A 2004 review describes what happened after the stop, writing that there is a trend for complete virological response to increase or accumulate gradually after the end of thymosin therapy. That is sometimes read as support for on-and-off use. It is not the same thing. It describes a hepatitis B virus count drifting down in the months after a single six-month course, measured in patients with the infection. A 1998 review was blunt about how unsettled the schedule was, calling for larger, well-planned clinical trials and also for defining the optimal schedule of administration. Among the research behind this page, that work on scheduling has not been published.

Question 10

Why do the published amounts barely vary?

Accepted Answer

Because the figure was carried forward from the early hepatitis trials rather than tested again. Most medicines reach a fixed amount through studies that compare several amounts and pick the one that balances effect against harm. In the sources behind this page, that step does not appear for thymosin alpha-1. The 2001 review gives the hepatitis C record as 162 patients in three clinical trials, and the hepatitis B record as 195 patients in four clinical trials. Those were the trials that fixed the figure, and later teams reused it in bowel cancer, lung cancer and pancreatitis. A uniform figure across a decade of trials can look like settled knowledge. It is better read as an inherited convention, which is weaker than a dose chosen by comparing doses.

Question 11

How do you reconstitute a thymosin alpha-1 vial?

Accepted Answer

No study behind this page describes mixing a vial, how much water to add, or how many injections a vial holds. Those are questions about a vial, and the trials used a finished medicine, named in one of them as thymalfasin for injection. What the research does say is that purity changes the arithmetic, and a 2022 analysis states that accurate purity assessment of thymalfasin material is essential for thymalfasin certified reference materials (CRMs) production. The same work warns that a full count of impurities is required to avoid quantitative bias, which means getting the measured amount wrong. If the reference standard itself needs that care, the number printed on an unlabelled vial is a claim rather than a measurement. The arithmetic of mixing is the same for any powder and is handled at the reconstitution calculator, but it can only be as accurate as the figure on the label.

Question 12

Does an approved dose apply to research-grade thymosin alpha-1?

Accepted Answer

No, and the reason is a matter of record rather than caution. A 2023 paper reports that the synthetic form, thymalfasin, has been approved by various regulatory agencies, and it names hepatitis B viral infection as the approved use. An approval belongs to a named medicine from a named maker, in the countries that granted it, for the illness it covers. It does not belong to the molecule wherever it turns up. The United States is where the line is drawn hardest, and a 2024 review recommends that the FDA permits 503A compounding pharmacies to compound Tα1. Those are pharmacies allowed to prepare a medicine for one named patient. That a review had to ask for this is the useful fact: even a pharmacy-made version was not permitted there when it was written, let alone a research vial with a label nobody has checked.

Question 13

Is anyone still testing the schedule?

Accepted Answer

Two registered trials sit among the sources behind this page, and neither is a dose-finding study. One is listed as Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer, a PHASE3 study marked RECRUITING. Adjuvant means given after surgery to lower the chance of the cancer coming back. The other is listed as Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine, a PHASE1 study. A phase 1 study is the earliest stage in people, and older adults getting a vaccine are the closest the record comes to people who are not already ill. Neither registry entry, as listed in these sources, gives a result.

Setting	Per injection	How often	Course
Hepatitis B, seven randomized studies	1.6 mg	Twice weekly	6 months
Hepatitis C, 40 subjects, with PEG-IFN and ribavirin	1.6 mg	Twice a week	48 weeks
After bowel cancer surgery	1.6 mg	Twice or thrice a week, by arm	Not stated here
Bowel cancer after chemotherapy, 2026	1.6 mg, under the skin	Twice weekly	8 weeks

Thymosin Alpha-1 protocols in the published literature